SLU-PP-332 Phase 1 Human Trial: Status, Timeline, and What ClinicalTrials.gov Shows

The Snapshot

As of mid-2026, SLU-PP-332 has not completed a well-characterized phase 1 human clinical trial with published results. Active interest in advancing the compound toward human trials exists within academic and biotechnology settings, and trial planning is visible in preprint servers and conference presentations, but the public clinical-trial registry does not yet contain a completed, results-reported phase 1 entry under the SLU-PP-332 name for a large-scale first-in-human study.

This post summarizes what the current regulatory and clinical-development footprint shows, the translational challenges SLU-PP-332 faces as a drug candidate, and how to read the signal going forward.

Why a Phase 1 Trial Matters

A phase 1 trial is the first formal human clinical evaluation of a drug candidate. It typically involves:

• Healthy volunteers or a narrowly defined patient population
• Small sample sizes (often 20–80 subjects)
• Single- and multiple-ascending-dose designs
• Primary endpoints focused on safety, tolerability, and pharmacokinetics rather than efficacy

For a compound with a notable preclinical cardiovascular signal — the resting heart rate finding in mice is the most prominent — a phase 1 trial is the first structured opportunity to observe the cardiovascular profile in humans under controlled exposure.

Translational Challenges for SLU-PP-332

Several features of SLU-PP-332’s preclinical profile have implications for how a phase 1 trial is likely to be designed:

Oral bioavailability is limited. Published preclinical work has relied on intraperitoneal dosing in mice. A translatable clinical formulation is a prerequisite for routine human development, and formulation work may have preceded phase 1 entry.

Cardiovascular telemetry is central. A phase 1 design for a compound with a preclinical heart rate signal will almost certainly include cardiac telemetry, Holter monitoring, and echocardiographic baseline and follow-up assessments.

Dose selection is nontrivial. Translating mouse IP doses of 50 mg/kg to human exposures requires allometric scaling, PK modeling, and no-observed-adverse-effect-level (NOAEL) analysis from repeat-dose toxicology in multiple species.

Primary endpoints. A first-in-human study for a compound in this space would likely evaluate safety and PK; a pharmacodynamic endpoint (e.g., changes in metabolic markers, heart rate, or exercise capacity) is often a secondary outcome.

What the Public Registry Currently Shows

Readers checking ClinicalTrials.gov for SLU-PP-332 as of this writing should be prepared for:

• Limited direct hits under the exact identifier “SLU-PP-332”
• Adjacent ERR-agonist programs from biotech entities working in the metabolic disease space
• Academic-sponsored pharmacology and mechanism-of-action studies that may use the compound as a research tool

The presence or absence of a specific trial listing should be verified on ClinicalTrials.gov itself, not inferred from secondary sources. Because the field is actively moving, updates to the registry are the most reliable source of current status information.

What to Watch Next

Clinicians and informed patients tracking SLU-PP-332 should watch for:

• Formulation announcements from academic groups or biotechnology partners — an oral or improved-PK formulation would materially advance the clinical path
• Preclinical expansion in non-rodent species — rat, dog, and non-human primate toxicology typically precedes human trials
• FDA pre-IND and IND activity — public visibility is limited, but conference abstracts and investor updates occasionally disclose status
• Peer-reviewed phase 1 results — the first published human safety/PK paper is the landmark that changes the conversation

Key Takeaways

• As of 2026, a well-characterized phase 1 trial of SLU-PP-332 with published results is not established in the public record.
• Translational hurdles — oral bioavailability, cardiovascular safety, dose scaling — are non-trivial.
• A phase 1 design for this compound will likely feature prominent cardiovascular monitoring.
• The ClinicalTrials.gov registry is the best single source for real-time trial status; secondary sources may lag.
• SLU-PP-332 is not available as a clinical therapy and should not be accessed through unregulated channels.

Frequently Asked Questions

Has SLU-PP-332 been tested in humans?

Published human data are limited. Human trial activity is in development, but a completed, results-reported phase 1 study is not a settled part of the dataset as of 2026.

Is there a clinical trial I can enroll in?

Patients asking about enrollment should check ClinicalTrials.gov directly. Enrollment in legitimate early-phase trials requires meeting narrowly defined eligibility criteria.

When will SLU-PP-332 be available?

No approved human indication exists. A plausible minimum timeline from completed phase 1 to potential approval — assuming everything goes well — is multiple years, with a substantial probability of the program stopping short.

Where can I follow updates?

ClinicalTrials.gov (registry), PubMed (peer-reviewed publications), and preprint servers (bioRxiv, medRxiv) are the most reliable public sources.